NCT00101114View on ClinicalTrials.gov

Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

May 31, 2006

Conditions
Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
Interventions
DRUG

sorafenib tosylate

Given PO

BIOLOGICAL

recombinant interferon alfa-2b

Given SC

OTHER

laboratory biomarker analysis

Optional correlative studies

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH